Takeda’s Alunbrig Receives FDA Accelerated Approval for Treatment of ALK+ Lung Cancer
News
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Takeda‘s Alunbrig (brigatinib) to treat ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who either progressed or could not ... Read more